Abstract 544P
Background
Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape. While programmed death-ligand 1 expression serves as a predictive biomarker, uncovering extra ICI response markers is pivotal. Immune cell transcriptomic analysis is a promising path for identifying such markers. Our study aims to find an ICI response predictor in lung adenocarcinoma patients' peripheral blood mononuclear cells (PBMC) through single-cell RNA sequencing (scRNA-seq).
Methods
We prospectively collected PBMC from 38 patients with stage IV lung adenocarcinoma, both before (0-7 days) and after (1-3 weeks) treatment with anti-PD(L)-1 therapy. Among the patients, 17 achieved a partial response, 4 had stable disease, and 17 experienced disease progression. Patients with a partial response or stable disease were classified as responders, while those with disease progression were classified as non-responders. We performed scRNA-seq on PBMC to unravel the molecular landscape.
Results
Subgroup analysis of NKT cells in pre-treated state revealed upregulated RNA expression related to activator protein 1 (AP-1) signals in NK cell subtypes (CD56lowCD16int NK cell, CCL4 NK cell, PTGDS NK cell) in responders. CD56 high CD16 low expressing NK cells were increased in responder after treatment with ICI. Additionally, we found an increased proportion of monocytes with high CXCL10 expression in the responder group. Signals associated with chemokine ligands and interferon-inducible proteins were upregulated in monocyte subtypes prior to ICI treatment.
Conclusions
Our scRNA-seq analysis of PBMC from lung adenocarcinoma patients provided valuable insights into the immune landscape. Upregulation of AP-1 signals in NK cells and chemokine ligand expression, as well as interferon-inducible signals in monocytes, were observed in responders prior to ICI treatment. Moreover, the expansion of monocytes with high CXCL10 expression in the responder group suggests the potential involvement of these circulating immune cell populations in the anti-tumor immune response. These findings contribute to our understanding of ICI response and offer promise for the future development of predictive biomarkers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract